Cytokinetics (CYTK) Operating Margin (2010 - 2026)
Cytokinetics (CYTK) posted quarterly Operating Margin of 948.69% for Q1 2026, up 890762.0% year-over-year from N/an in Q1 2025, and up 5.57% quarter-over-quarter from 1004.6% in Q4 2025.
Cytokinetics (CYTK) Operating Margin (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Operating Margin for 17 consecutive years, with 948.69% the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Margin rose 890762.0% year-over-year to 948.69%; the TTM figure through Mar 2026 stood at 605.06% (up 266626.0% YoY), while the FY2025 annual figure was 695.44%, up 287955.0% from the prior year.
- Operating Margin rose to 948.69% in Q1 2026 per CYTK's latest filing, from 1004.6% in the prior quarter.
- Across five years, Operating Margin topped out at 12.22% in Q2 2022 and bottomed at 52277.91% in Q2 2024.
- Historically, Operating Margin has averaged 11391.87% across 5 years, with a median of 6781.97% in 2022.
- Annual changes were most pronounced in 2024 — Operating Margin slumped 3820075 bps — and 2025, when it surged 5211091 bps.
- Cytokinetics' Operating Margin stood at 6491.06% in 2022, then retreated by 17 bps to 7620.69% in 2023, then surged by 88 bps to 926.93% in 2024, then declined by 8 bps to 1004.6% in 2025, then grew by 6 bps to 948.69% in 2026.
- Business Quant data shows CYTK's Operating Margin at 948.69% in Q1 2026, 1004.6% in Q4 2025, and 8613.38% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | -625.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -625.95% |
| Mar 31, 2026 | -948.69% |
| Dec 31, 2025 | -1,004.60% |
| Sep 30, 2025 | -8,613.38% |
| Jun 30, 2025 | -167.00% |
| Mar 31, 2025 | -9,856.30% |
| Dec 31, 2024 | -926.93% |
| Sep 30, 2024 | -30,410.58% |
| Jun 30, 2024 | -52,277.91% |
| Mar 31, 2024 | -15,117.96% |
| Dec 31, 2023 | -7,620.69% |
| Sep 30, 2023 | -32,345.24% |
| Jun 30, 2023 | -14,077.16% |
| Mar 31, 2023 | -2,698.31% |
| Dec 31, 2022 | -6,491.06% |
| Sep 30, 2022 | -4,311.77% |
| Jun 30, 2022 | -12.22% |
| Mar 31, 2022 | -6,781.97% |
| Dec 31, 2021 | -54.16% |
| Sep 30, 2021 | -1,272.78% |